The technology, based on research from Stanford University, will be integrated into Leo Cancer Care platforms with the first installation at Mayo Clinic.
TibaRay, a Silicon Valley medical technology company, announced that its Galactica cancer treatment systems have entered the manufacturing phase. The technology is based on research from Stanford University and represents a new class of medical linear accelerator designed for clinical deployment.
The Galactica system is designed for integration into an upright radiotherapy platform, allowing patients to be treated while sitting or standing rather than lying down. According to the company, this approach improves patient comfort while enabling high-precision treatment and reducing the overall size of the system.
While nearly two-thirds of cancer patients benefit from radiotherapy, many healthcare facilities continue to use linear accelerators developed decades ago. These systems are often large, expensive to install, and limited in precision.
“For years, our team has focused on solving radiation oncology’s biggest challenge of making treatment more precise, more accessible, and ultimately available to more patients,” says Thinh Tran, CEO of TibaRay, in a release. “Moving into manufacturing means Galactica is coming to life. We have reached a major engineering milestone that transforms years of innovation into a technology ready for real-world clinical deployment.”
The proprietary technology generates the high-energy X-rays used to treat cancer in a smaller, more efficient system. TibaRay aims to improve treatment precision while reducing the cost and complexity associated with advanced radiotherapy equipment.
The system also serves as the foundation for the company’s long-term goal of enabling FLASH, an emerging treatment option. Researchers believe FLASH has the potential to eliminate tumors while minimizing damage to surrounding healthy tissue by delivering radiotherapy in a fraction of a second.
The manufacturing milestone is the latest step in the company’s implementation strategy as it prepares for its first clinical installations. The systems will be integrated into the Leo Cancer Care radiotherapy platform, with the first installation planned for later this year at Mayo Clinic.
Photo caption: Galactica system
Photo credit: TibaRay
